Soghra Jarvandi1, Maria Pérez2, Mario Schootman3,4, Donna B Jeffe2,4. 1. Department of Family and Consumer Sciences, University of Tennessee, Knoxville, TN, 37996, USA. sjarvand@utk.edu. 2. Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO, 63110, USA. 3. College for Public Health and Social Justice, Saint Louis University, Saint Louis, MO, 63104, USA. 4. Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Saint Louis, MO, 63110, USA.
Abstract
PURPOSE: Type 2 diabetes is a common comorbidity among breast cancer survivors. Our aim was to assess the association between diabetes and quality of life (QOL) in newly diagnosed early stage (0-IIA) breast cancer patients over a 2-year follow-up. METHODS: We used data from a longitudinal study of 549 breast cancer patients, aged ≥40 years. During four telephone interviews administered 4-6 weeks and 6, 12, and 24 months after definitive surgical treatment, we measured QOL using the Functional Assessment of Cancer Therapy-Breast (FACT-B) scale; higher scores indicate better QOL. Repeated measures analysis of variance was used to test the change over time in total FACT-B and each of the five subscales (physical, social, emotional and functional well-being, and breast cancer concerns), comparing patients with and without diabetes at baseline. RESULTS: After adjusting for covariates (age, race, body mass index, education, marital status, cancer staging, and surgical side effects), patients with (vs. without) diabetes reported lower QOL over time on the total FACT-B (least-squares mean [standard error] 106.2 [2.1] vs. 112.0 [1.1]; p = 0.0038) and on physical, social, emotional, and functional well-being subscales (each p < 0.05). Over the 2-year follow-up, QOL improved significantly for the emotional well-being (p < 0.0001) and breast cancer concern subscales (p = 0.0282) among patients without diabetes, but not among patients with diabetes. CONCLUSION: Early stage breast cancer patients with diabetes may need additional care considerations to improve QOL.
PURPOSE:Type 2 diabetes is a common comorbidity among breast cancer survivors. Our aim was to assess the association between diabetes and quality of life (QOL) in newly diagnosed early stage (0-IIA) breast cancerpatients over a 2-year follow-up. METHODS: We used data from a longitudinal study of 549 breast cancerpatients, aged ≥40 years. During four telephone interviews administered 4-6 weeks and 6, 12, and 24 months after definitive surgical treatment, we measured QOL using the Functional Assessment of Cancer Therapy-Breast (FACT-B) scale; higher scores indicate better QOL. Repeated measures analysis of variance was used to test the change over time in total FACT-B and each of the five subscales (physical, social, emotional and functional well-being, and breast cancer concerns), comparing patients with and without diabetes at baseline. RESULTS: After adjusting for covariates (age, race, body mass index, education, marital status, cancer staging, and surgical side effects), patients with (vs. without) diabetes reported lower QOL over time on the total FACT-B (least-squares mean [standard error] 106.2 [2.1] vs. 112.0 [1.1]; p = 0.0038) and on physical, social, emotional, and functional well-being subscales (each p < 0.05). Over the 2-year follow-up, QOL improved significantly for the emotional well-being (p < 0.0001) and breast cancer concern subscales (p = 0.0282) among patients without diabetes, but not among patients with diabetes. CONCLUSION: Early stage breast cancerpatients with diabetes may need additional care considerations to improve QOL.
Entities:
Keywords:
Breast cancer; Cohort study; Diabetes; Functional Assessment of Cancer Therapy-Breast (FACT-B); Quality of life; Surgical side effects
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Ying Liu; Maria Pérez; Mario Schootman; Rebecca L Aft; William E Gillanders; Matthew J Ellis; Donna B Jeffe Journal: Breast Cancer Res Treat Date: 2010-05-06 Impact factor: 4.872
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Kimberly S Peairs; Bethany B Barone; Claire F Snyder; Hsin-Chieh Yeh; Kelly B Stein; Rachel L Derr; Frederick L Brancati; Antonio C Wolff Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: Margaret A Olsen; Mellani Lefta; Jill R Dietz; Keith E Brandt; Rebecca Aft; Ryan Matthews; Jennie Mayfield; Victoria J Fraser Journal: J Am Coll Surg Date: 2008-06-26 Impact factor: 6.113
Authors: Rana El Haidari; Amelie Anota; Tienhan S Dabakuyo-Yonli; Francis Guillemin; Thierry Conroy; Michel Velten; Damien Jolly; Sylvain Causeret; Jean Cuisenier; Olivier Graesslin; Linda Abou Abbas; Virginie Nerich Journal: Qual Life Res Date: 2022-05-19 Impact factor: 3.440
Authors: Roy Rillera Marzo; Sudip Bhattacharya; Soe Soe Aye; Shailesh Tripathi; Thein Win Naing; Maung Maung Soe; Ye Wint Kyaw; Cyril Deeben A L Richard Packiam; Donnington Chai Ping Ping; Puteri Maisarah Binti Zolpakar; Vethashini A P Selvakumar; Saidatur Raihan Binti Abdul Ali; Auni Fajriyah Binti Hasrudin; Joshua Sutikno Journal: J Public Health Res Date: 2022-05-16
Authors: Beomyoung Cho; Maria Pérez; Donna B Jeffe; Matthew W Kreuter; Julie A Margenthaler; Graham A Colditz; Ying Liu Journal: BMC Cancer Date: 2022-08-01 Impact factor: 4.638